9,339 results match your criteria Breast Cancer Res. Treat.[Journal]


Sensory profiles in women with neuropathic pain after breast cancer surgery.

Breast Cancer Res Treat 2020 May 27. Epub 2020 May 27.

Division of Pain Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, Pain Clinic, University of Helsinki and Helsinki University Hospital, P.O. Box 140, 00029 HUS, Helsinki, Finland.

Purpose: We performed a detailed analysis of sensory function in patients with chronic post-surgical neuropathic pain (NP) after breast cancer treatments by quantitative sensory testing (QST) with DFNS (German Research Network on Neuropathic Pain) protocol and bed side examination (BE). The nature of sensory changes in peripheral NP may reflect distinct pathophysiological backgrounds that can guide the treatment choices. NP with sensory gain (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05681-8DOI Listing

A comparison of two non-radioactive alternatives to wire for the localization of non-palpable breast cancers.

Breast Cancer Res Treat 2020 May 25. Epub 2020 May 25.

Department of Surgery, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA, 90095, USA.

Purpose: Multiple wire-free technologies for localization of non-palpable breast cancers have emerged as satisfactory alternatives to wire. However, no study has compared two non-radioactive wire-free approaches to one another. The purpose of this study was to compare outcomes among LOCalizer™ radiofrequency identification (RFID), SAVI Scout® (SAVI), and wire localization (WL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05707-1DOI Listing

Does oncoplastic surgery increase immediate (30-day) postoperative complications? An analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database.

Breast Cancer Res Treat 2020 May 25. Epub 2020 May 25.

Division of General Surgery, Department of Surgery, University of Toronto, Toronto, ON, Canada.

Purpose: Although there has been a significant increase in the use of oncoplastic surgery (OPS), data on the postoperative safety of this approach are limited compared to traditional lumpectomy. This study aimed to compare the immediate (30-day) postoperative complications associated with OPS and traditional lumpectomy.

Methods: An analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database was performed on women with breast cancer who underwent OPS or traditional lumpectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05665-8DOI Listing

Diffusion-weighted MRI at 3.0 T for detection of occult disease in the contralateral breast in women with newly diagnosed breast cancer.

Breast Cancer Res Treat 2020 May 23. Epub 2020 May 23.

Department of Radiology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Republic of Korea.

Purpose: Diffusion-weighted magnetic resonance imaging (DW-MRI) offers unenhanced method to detect breast cancer without cost and safety concerns associated with dynamic contrast-enhanced (DCE) MRI. Our purpose was to evaluate the performance of DW-MRI at 3.0T in detection of clinically and mammographically occult contralateral breast cancer in patients with unilateral breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05697-0DOI Listing

Real-world evaluation of effectiveness and tolerance of chemotherapy for early-stage breast cancer in older women.

Breast Cancer Res Treat 2020 May 23. Epub 2020 May 23.

Division of Hematology/Oncology, West Cancer Center/University of Tennessee Health Science Center, 7945 Wolf River Boulevard, Germantown, Memphis, TN, USA.

Purpose: Older patients with early-stage breast cancer (ESBC) tend to receive less aggressive treatment, have higher mortality rates, and are underrepresented in clinical trials. Outcomes, tolerance and toxicity of chemotherapy are underreported. Thus, we assessed the outcomes of chemotherapy in the real-world in a community oncology setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05684-5DOI Listing

Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.

Breast Cancer Res Treat 2020 May 22. Epub 2020 May 22.

Nottingham Breast Cancer Research Centre, School of Medicine, University of Nottingham, Nottingham, UK.

Purpose: MMP9 is a matricellular protein associated with extracellular matrix (ECM) remodelling, that promotes tumour progression, and modulates the activity of cell adhesion molecules and cytokines. This study aims to assess the prognostic value of MMP9 and its association with cytoskeletal modulators in early-stage invasive breast cancer (BC).

Methods: MMP9 expression was evaluated by immunohistochemistry using a well-characterised series of primary BC patients with long-term clinical follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05670-xDOI Listing

Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.

Breast Cancer Res Treat 2020 May 22. Epub 2020 May 22.

Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Purpose: Identification of inherited breast cancer may guide cancer risk management. We sought to compare risk management practices across women with inherited breast cancer genes.

Methods: Females with a pathogenic/likely pathogenic (P/LP) variant in BRCA1/2, PALB2, CHEK2, and/or ATM were surveyed about cancer risk management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05699-yDOI Listing

Synchronous bilateral breast cancer: a nationwide study on histopathology and etiology.

Breast Cancer Res Treat 2020 May 21. Epub 2020 May 21.

Department of Pathology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.

Purpose: The aim of the present study was to describe histopathologic characteristics of synchronous bilateral breast cancer (SBBC), and by comparing SBBC to unilateral breast cancer (UBC), identify possible etiological mechanisms of SBBC.

Methods: Patients with primary SBBC (diagnosed within 4 months) and UBC diagnosed in Denmark between 1999 and 2015 were included. Detailed data on histopathology were retrieved from the Danish Breast Cancer Group database and the Danish Pathology Register. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05689-0DOI Listing

Radiation and/or endocrine therapy? Recurrence and survival outcomes in women over 70 with early breast cancer after breast-conserving surgery.

Breast Cancer Res Treat 2020 May 21. Epub 2020 May 21.

Department of Radiation Oncology, Dalhousie University, 5820 University Avenue, Halifax, NS, B3H 1V7, Canada.

Purpose: Women over 70 with early breast cancer treated with breast-conserving surgery are typically offered adjuvant endocrine and radiation therapy. Prior studies have supported the omission of adjuvant radiation in this low-risk population. We sought to compare the effect of adjuvant treatment with endocrine therapy alone, radiation therapy alone or both versus no adjuvant treatment on local control and survival in this population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05691-6DOI Listing

Reply to letters to the editor: Discordance in estrogen receptor and change of Ki67 between primary site and metastatic site of recurrent breast cancer.

Breast Cancer Res Treat 2020 May 21. Epub 2020 May 21.

Division of Breast Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Shizuoka, 4118777, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05695-2DOI Listing

Somatic mutations of triple-negative breast cancer: a comparison between Black and White women.

Breast Cancer Res Treat 2020 May 21. Epub 2020 May 21.

Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY, 14263, USA.

Purpose: Understanding the contribution of tumor genome biology to racial disparities of triple-negative breast cancer (TNBC) is important for narrowing the cancer mortality gap between Black and White women.

Methods: We evaluated tumor somatic mutations using targeted sequencing of a customized panel of 151 genes and 15 copy number variations (CNVs) within a population of 133 TNBC patients, including 71 Black and 62 White women.

Results: The overall mutational burden between Black and White women with TNBC was not significantly different, with a median of 5 somatic changes per patient (point mutations and CNVs combined) for the customized panel (range 1-31 for Blacks vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05693-4DOI Listing

Androgen receptor expression inversely correlates with histological grade and N stage in ER/PgR male breast cancer.

Breast Cancer Res Treat 2020 May 21. Epub 2020 May 21.

Division of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Purpose: Androgen Receptor (AR) positivity is often displayed in breast cancer and especially in Male Breast Cancer (MBC), where it appears to be a heterogeneous feature, with its expression ranging between 38 and 81% of cases. Given the fact that circulating androgens represent the most important sex hormones in males and that breast carcinogenesis is characteristically subjected to hormonal mechanisms, our purpose was to investigate the clinicopathological significance of AR in MBC assessing if its expression could be associated with parameters of tumor aggressiveness.

Methods: Clinical and pathological data were retrospectively reviewed for male patients with a diagnosis of invasive breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05682-7DOI Listing

Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study.

Breast Cancer Res Treat 2020 May 20. Epub 2020 May 20.

Department of Oncology, Oslo University Hospital, Oslo, Norway.

Purpose: Whether an unfavorable lifestyle not only affects breast cancer risk, but also influences age at onset of breast cancer and survival, is under debate.

Methods: In a population-based cohort, the Energy Balance and Breast Cancer Aspects throughout life (EBBA-Life) study, a total of 17,145 women were included. During follow-up, 574 women developed invasive breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05679-2DOI Listing

HER2-targeted therapy influences CTC status in metastatic breast cancer.

Breast Cancer Res Treat 2020 May 20. Epub 2020 May 20.

Department of Gynecology and Obstetrics, University Hospital Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany.

Purpose: As an independent, negative-prognostic biomarker for progression-free survival (PFS) and overall survival (OS), circulating tumor cells (CTCs) constitute a promising component for developing a liquid biopsy for patients with metastatic breast cancer (MBC). The effects of HER2-targeted therapy such as trastuzumab, pertuzumab, T-DM1, and lapatinib on CTC status and longitudinal enumeration were assessed in this trial.

Methods: CTC status of 264 patients with MBC was analyzed prior to and after 4 weeks of a new line of palliative systemic therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05687-2DOI Listing

EndoPredict in early hormone receptor-positive, HER2-negative breast cancer.

Breast Cancer Res Treat 2020 May 20. Epub 2020 May 20.

Department of Obstetrics and Gynecology, University Medical Center Mainz, Langenbeckstr. 1, 55131, Mainz, Germany.

Purpose: Evaluating consecutive early breast cancer patients, we analyzed both the impact of EndoPredict on clinical decisions as well as clinico-pathological factors influencing the decision to perform this gene expression test.

Methods: Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer patients treated between 2011 and 2016 were included in this study to investigate the role of EndoPredict (EPclin) in the treatment of early breast cancer. A main study aim was to analyze the changes in therapy recommendations with and without EPclin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05688-1DOI Listing

Fertility and reproduction in breast cancer patients.

Breast Cancer Res Treat 2020 May 20. Epub 2020 May 20.

Università degli Studi Sapienza, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05676-5DOI Listing

Breast-conserving surgery without axillary lymph node surgery or radiotherapy is safe for HER2-positive and triple negative breast cancer patients over 70 years of age.

Breast Cancer Res Treat 2020 May 19. Epub 2020 May 19.

Department of Breast Disease, Peking Union Medical College Hospital, No. 1 Shuaifuyuan, Wangfujing, Beijing, 100730, China.

Purpose: The prognosis of elderly patients with hormone receptor-positive breast cancer is very good, and their survival is unaffected by performing breast-conserving surgery (BCS) without radiotherapy. Therefore, we aimed to verify that BCS without axillary lymph node dissection, sentinel lymph node biopsy, or radiotherapy (BCSNR) is safe for patients over 70 years of age with luminal-type breast cancer, as well as for those with HER2-positive and triple negative breast cancer (TNBC).

Methods: This study retrospectively included 450 patients > 70-year-old with breast cancer from 2010 to 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05686-3DOI Listing
May 2020
3.940 Impact Factor

Patients' perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict.

Breast Cancer Res Treat 2020 May 19. Epub 2020 May 19.

Department of Surgery, Diakonessenhuis Utrecht, Utrecht, The Netherlands.

Purpose: Little is known about the impact of 70-gene signature (70-GS) use on patients' chemotherapy decision-making. The primary aim of this study was to evaluate the impact of 70-GS use on patients' decisions to undergo chemotherapy. The perceived decision conflict during decision-making was a secondary objective of the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05683-6DOI Listing

Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good?

Breast Cancer Res Treat 2020 May 19. Epub 2020 May 19.

Primrose Breast Unit, Derriford Hospital, University Hospitals Plymouth NHS Trust, Plymouth, PL6 8DH, Devon, UK.

Purpose: Ductal carcinoma in situ (DCIS) of the breast does not metastasize to axillary lymph nodes. Yet high-grade DCIS (HgDCIS) is often subjected to Sentinel Lymph Node Biopsy (SLNB) concomitant with definitive surgery. This is to avoid further axillary surgery in the event of upstaging to invasive carcinoma, which often entails Axillary Lymph Node Dissection (ALND). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05690-7DOI Listing

High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer.

Breast Cancer Res Treat 2020 May 18. Epub 2020 May 18.

Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Hongkou District, Shanghai, 200080, China.

Purpose: Oxidative stress-responsive kinase 1 (OSR1) plays a crucial role in regulating diverse cellular pathophysiologic functions, including ion homeostasis, development, differentiation, angiogenesis, invasive migration, and metastasis. Regardless, the clinical significance of OSR1 in breast cancer is scarce. The current study was conducted to evaluate the effect of OSR1 on the prognosis of patients with breast cancer with a long-term follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05671-wDOI Listing
May 2020
3.940 Impact Factor

Association between thyroid gland diseases and breast cancer: a case-control study.

Breast Cancer Res Treat 2020 May 18. Epub 2020 May 18.

Department of Gynecology and Obstetrics, Philipps University of Marburg, Marburg, Germany.

Background: At the present time, there is no consensus on the association between benign thyroid diseases and breast cancer (BC). Therefore, the aim of this study is to help shed some light on the association between hyperthyroidism, hypothyroidism, and thyroiditis and breast cancer risk.

Methods: Use of the Disease Analyzer database (IQVIA) enabled us to perform a retrospective case-control study of 7408 women aged between 18 and 80, who were treated for an initial breast cancer diagnosis in a general practice in the United Kingdom between 2006 and 2015 (index date). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05675-6DOI Listing

ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer.

Breast Cancer Res Treat 2020 May 16. Epub 2020 May 16.

First Department of Medical Oncology, AGIOS SAVVAS Athens General Hospital, Athens, Greece.

Purpose: The efficacy of nab-paclitaxel in patients with metastatic breast cancer (MBC) has been demonstrated in randomized clinical trials. However, real-world evidence on effectiveness remains limited.

Patients And Methods: The primary objective of this multicenter prospective study was to assess the overall response rate (ORR) of patients with MBC treated with nab-paclitaxel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05677-4DOI Listing

Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.

Breast Cancer Res Treat 2020 May 16. Epub 2020 May 16.

Department of Surgery, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.

Purpose: Accurate prediction of pathologic complete response (pCR) in breast cancer using magnetic resonance imaging (MRI) and ultrasound (US)-guided biopsy may aid in selecting patients who forego surgery for breast cancer. We evaluated the accuracy of US-guided biopsy aided by MRI in predicting pCR in the breast after neoadjuvant chemotherapy (NAC).

Methods: After completion of NAC, 40 patients with near pCR (either tumor size ≤ 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05678-3DOI Listing

Long-term excess body fat in adulthood and the risk of pre- and postmenopausal breast cancer in Chinese women.

Breast Cancer Res Treat 2020 May 15. Epub 2020 May 15.

Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, No. 16 Ren Min Nan Lu, Chengdu, 610041, Sichuan, China.

Purpose: This study aimed to investigate the association between long-term excess body fat and breast cancer risk by studying adult weight gain together with the subsequent weight fluctuations.

Methods: Weight gain measure in three different time periods in adulthood of 1500 participants was collected in a case-control study of Western China. Logistic regression models were used to estimate odds ratios and 95% CIs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05685-4DOI Listing

TRPC1 inhibits the proliferation and migration of estrogen receptor-positive Breast cancer and gives a better prognosis by inhibiting the PI3K/AKT pathway.

Breast Cancer Res Treat 2020 May 15. Epub 2020 May 15.

Outpatient Department of Breast Center, Cancer Hospital of Shantou University Medical College, No. 7 Raoping Road, Shantou, 515031, People's Republic of China.

Purpose: Previous studies have indicated that transient receptor potential (TRP) channels can influence cancer development. The TRPC subfamily consists of seven subtypes, TRPC1 - TRPC7. Interestingly, the expression levels of TRPC1 have been shown to be totally different in different breast cancer cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05673-8DOI Listing

Lipid biosignature of breast cancer tissues by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Breast Cancer Res Treat 2020 May 15. Epub 2020 May 15.

CQM - Centro de Química da Madeira, Universidade da Madeira, Campus Universitário da Penteada, 9020-105, Funchal, Portugal.

Purpose: One of the hallmarks of cancer cells is the demand of supply for the synthesis of new membranes involved in cell proliferation and lipids have an important role in cellular structure, signaling pathways and progression of cancer. In this sense, lipid studies have become an essential tool allowing the establishment of signatures associated with breast cancer (BC). In this regard, some metabolic processes including proteins, nucleic acids and lipid synthesis are enhanced as part of cancer-associated metabolic reprogramming, as a requirement for cell growth and proliferation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05672-9DOI Listing

The effect of vitamin D supplementation on the risk of breast cancer: a trial sequential meta-analysis.

Breast Cancer Res Treat 2020 May 13. Epub 2020 May 13.

Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.

Background And Objective: Observational studies suggest an inverse association between circulating vitamin D levels and risk of breast cancer. However, the potential benefits of vitamin D supplementation to reduce the risk of breast cancer remain controversial, based on the results of current randomized controlled trials (RCTs). The aim of this study was to evaluate the value of vitamin D supplementation on breast cancer prevention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05669-4DOI Listing

The natural history of untreated estrogen receptor-positive, Her2-negative invasive breast cancer.

Breast Cancer Res Treat 2020 May 12. Epub 2020 May 12.

Department of Surgery, Maimonides Medical Center, Brooklyn, USA.

Background: Using prior mammograms from patients with delays in their breast cancer diagnoses, we sought to describe in-vivo growth kinetics of untreated breast cancer to determine if the time they became clinically apparent can be predicted.

Methods: Patient and tumor characteristics were collected from those who presented with "missed," untreated breast cancer to a breast center in a single institution. Only patients whose biopsied masses revealed estrogen receptor-positive, Her2-negative (ER+/Her2-) invasive cancers were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05666-7DOI Listing

Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study.

Breast Cancer Res Treat 2020 May 12. Epub 2020 May 12.

Kobe University Hospital, Kobe, Japan.

Purpose: To examine the association of physical activity (PA) with bone health among patients with breast cancer receiving adjuvant aromatase inhibitor (AI) treatment.

Methods: In this single-center observational study, we enrolled postmenopausal women with primary hormone receptor-positive breast cancer who were receiving adjuvant AI treatment. We assessed patient bone health [bone mineral density (BMD) and biomarkers of bone turnover] as main outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05668-5DOI Listing

Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.

Breast Cancer Res Treat 2020 May 11. Epub 2020 May 11.

National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Purpose: Platinum plays an important role in the treatment of triple-negative breast cancer (TNBC) in neoadjuvant and metastatic settings. However, its role in an adjuvant setting remains unclear.

Methods: In this non-inferior randomized phase 2 trial, we randomly assigned 308 chemotherapy-naive patients with histologically confirmed TNBC after primary surgery to receive either six cycles of TP (docetaxel: 75 mg/m or paclitaxel 175 mg/m d1; carboplatin AUC = 5, day 1), or four cycles of EC (epirubicin: 90 mg/m; cyclophosphamide: 600 mg/m, day 1) followed by four cycles of T (docetaxel: 75 mg/m or paclitaxel 175 mg/m, day 1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05648-9DOI Listing

Racial/ethnic differences in supplemental imaging for breast cancer screening in women with dense breasts.

Breast Cancer Res Treat 2020 May 11. Epub 2020 May 11.

Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Background: Mammography is limited when analyzing dense breasts for 2 reasons: (1) breast density masks underlying cancers and (2) breast density is an independent risk factor for cancer. We undertook this study to assess whether there is a racial/ethnic difference in supplemental image ordering for women with dense breasts.

Methods: We conducted a retrospective, observational cohort study of women aged 50-75 from an academic medical center who had completed a screening mammogram between 2014 and 2016 that was read as BI-RADS 1 with heterogeneously or extremely dense breasts or BI-RADS 2 with extremely dense breasts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05652-zDOI Listing

Association between the polymorphisms in MMP-2 and MMP-9 with adiposity and mammographic features.

Breast Cancer Res Treat 2020 May 11. Epub 2020 May 11.

Centre de Recherche du CHU de Québec-Université Laval (axe oncologie), Centre de Recherche sur le Cancer de L'Université Laval et Département de médecine Sociale et préventive, Faculté de médecine, Université Laval, 1050 Chemin Sainte-Foy, Quebec, QC, G1S 4L8, Canada.

Background: Matrix metalloproteinases (MMP)-2 and -9 may play an important role in adipogenesis and carcinogenesis. We investigated whether some polymorphisms located in these genes are associated with body adiposity and mammographic breast density, which are risk factors for breast cancer.

Methods: Our study population included 731 premenopausal women. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05651-0DOI Listing

The impact of ductal carcinoma in situ on health services utilization.

Breast Cancer Res Treat 2020 May 8. Epub 2020 May 8.

University of Toronto, Sunnybrook Research Institute, T2-152 - 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.

Purpose: To determine the intermediate-term impact of diagnosis and treatment of ductal carcinoma in situ of the breast (DCIS) on health services utilization, we compared utilization by cases of DCIS to unaffected controls.

Methods: We identified a population-based cohort of Ontario females diagnosed with DCIS between 2010 and 2015. We matched 5 controls without any history of cancer to each case, on the date of diagnosis of the case (the index date), by age, annual mammography history, socioeconomic status, and comorbidity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05664-9DOI Listing

Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.

Breast Cancer Res Treat 2020 May 8. Epub 2020 May 8.

Department of Pharmacology, Centre for Advanced Research in Pharmacogenomics, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.

Purpose: Musculoskeletal adverse events (MS-AEs) and vasomotor symptoms (VMSs) are the major side-effects of newer generation non-steroidal aromatase inhibitor (AI), letrozole. Single-nucleotide polymorphisms (SNPs) in CYP19A1 gene coding for the enzyme aromatase are related to AI treatment-associated adverse drug reactions. Therefore, we aimed to determine whether SNPs in the CYP19A1 gene are associated with adjuvant letrozole-induced 'specific' AEs in postmenopausal hormone receptor-positive (HR+) breast cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05656-9DOI Listing

Chemotherapy use near the end-of-life in patients with metastatic breast cancer.

Breast Cancer Res Treat 2020 Jun 7;181(3):645-651. Epub 2020 May 7.

Department of Oncology/Pathology, Karolinska Institutet, Stockholm, Sweden.

Introduction: Very few data are available regarding the use of chemotherapy in patients with metastatic breast cancer (MBC) near the end-of-life, i.e., the final month. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05663-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220858PMC

Assessing breast lymphoedema following breast cancer treatment using indocyanine green lymphography.

Breast Cancer Res Treat 2020 Jun 6;181(3):635-644. Epub 2020 May 6.

Department of Health Professions, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.

Purpose: Breast lymphoedema is a largely unrecognised survivorship issue for women following breast cancer treatment. While a few objective methods have previously been applied to assess breast lymphoedema, none are capable of imaging breast lymphatics or identifying lymphatic morphological changes indicative of breast lymphoedema. The purpose of this study was to determine if indocyanine green (ICG) lymphography, a validated assessment technique in breast cancer-related lymphoedema), can visualise breast lymphatics and identify breast lymphoedema. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05661-yDOI Listing
June 2020
3.940 Impact Factor

Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy.

Breast Cancer Res Treat 2020 Jun 6;181(3):571-580. Epub 2020 May 6.

Department of Histopathology, Trinity College Dublin and Emer Casey Molecular Pathology Research Laboratory, Coombe Women's and Infants University Hospital, Dublin, Ireland.

Purpose: The association between pathological complete response (pCR) in patients receiving neoadjuvant chemotherapy (NAC) for breast cancer and Circulating Tumour Cells (CTCs) is not clear. The aim of this study was to assess whether CTC enumeration could be used to predict pathological response to NAC in breast cancer as measured by the Miller-Payne grading system.

Methods: Twenty-six patients were recruited, and blood samples were taken pre- and post-NAC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05658-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220879PMC

Healthcare providers' adherence to breast cancer guidelines in Europe: a systematic literature review.

Breast Cancer Res Treat 2020 Jun 6;181(3):499-518. Epub 2020 May 6.

CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Purpose: Clinical guidelines' (CGs) adherence supports high-quality care. However, healthcare providers do not always comply with CGs recommendations. This systematic literature review aims to assess the extent of healthcare providers' adherence to breast cancer CGs in Europe and to identify the factors that impact on healthcare providers' adherence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05657-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220981PMC

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.

Breast Cancer Res Treat 2020 Jun 6;181(3):623-633. Epub 2020 May 6.

The University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL, 60637, USA.

Purpose: Capecitabine is important in breast cancer treatment but causes diarrhea and hand-foot syndrome (HFS), affecting adherence and quality of life. We sought to identify pharmacogenomic predictors of capecitabine toxicity using a novel monitoring tool.

Methods: Patients with metastatic breast cancer were prospectively treated with capecitabine (2000 mg/m/day, 14 days on/7 off). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05603-8DOI Listing

Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.

Breast Cancer Res Treat 2020 Jun 4;181(3):679-689. Epub 2020 May 4.

Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.

Purpose: Discordance between HER2 expression in tumor tissue (tHER2) and HER2 status on circulating tumor cells (cHER2) has been reported. It remains largely underexplored whether patients with tHER2/cHER2 can benefit from anti-HER2 targeted therapies.

Methods: cHER2 status was determined in 105 advanced-stage patients with tHER2 breast tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05662-xDOI Listing

Value of CXCL8-CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study.

Breast Cancer Res Treat 2020 Jun 2;181(3):561-570. Epub 2020 May 2.

Department of Breast Surgery, Fudan University Shanghai Cancer Center/Cancer Institute, 399 Ling-Ling Road, Shanghai, 200032, People's Republic of China.

Background: In this study we investigate the prediction and prognostic value of CXCL8-CXCR1/2 axis for Triple-negative breast cancer (TNBC) patients underwent neoadjuvant chemotherapy (NAC) following standard radical surgery.

Methods: A total of 303 TNBC patients were included in this study. The NAC regimen was weekly paclitaxel plus carboplatin (PC) for all patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05660-zDOI Listing

PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies.

Breast Cancer Res Treat 2020 Jun 2;181(3):553-560. Epub 2020 May 2.

Department of Pathology, Herlev and Gentofte Hospital, University of Copenhagen, Borgmester Ib Juuls vej 1, 2730, Herlev, Denmark.

Purpose: PD-L1 expression is a predictive biomarker for anti-PD-L1 immunotherapy in triple negative breast cancer (TNBC). In the neoadjuvant setting, immunohistochemical (IHC) evaluation of PD-L1 expression can only be performed on small tissue biopsies. In our study we investigated heterogeneity of PD-L1 expression in TNBC, and how reliably PD-L1 expression in small tissue samples reflects PD-L1 expression in larger tumor sections in TNBC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05655-wDOI Listing

Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study.

Breast Cancer Res Treat 2020 Jun 30;181(3):667-678. Epub 2020 Apr 30.

Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.

Purpose: The objective of this study is to analyse the relative survival with breast cancer in women diagnosed after new treatments were generalised and to ascertain the current effect that tumour characteristics such as grade, stage or subtype have on survival as well as the new AJCC-pathological prognostic score.

Methods: The breast cancer MCC-Spain follow-up study is a prospective cohort study of 1685 incident breast cancer cases. Women between 20 and 85 years old were recruited between the years 2008 and 2013 in 18 hospitals located in 10 Spanish provinces and they have been followed until 2017/2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05600-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220874PMC
June 2020
3.940 Impact Factor

A prospective cohort study to analyze the interaction of tumor-to-breast volume in breast conservation therapy versus mastectomy with reconstruction.

Breast Cancer Res Treat 2020 Jun 30;181(3):611-621. Epub 2020 Apr 30.

Division of Plastic & Reconstructive Surgery, Department of Surgery, Washington University School of Medicine, 1020 N. Mason, Ste 110, St. Louis, MO, USA.

Purpose: We explored the impact of the relative volume of a tumor versus the entire breast on outcomes in patients undergoing breast conservation therapy (BCT) versus mastectomy and reconstruction (M + R). We hypothesized that there would be a threshold tumor:breast ratio (TBR) below which patient-reported outcomes (PRO) would favor BCT and above which would favor M + R.

Methods: We conducted a prospective cohort study of patients with ductal carcinoma in situ (DCIS) or invasive breast cancers undergoing BCT or M + R. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05639-wDOI Listing
June 2020
3.940 Impact Factor

Anti-HER2 therapy for metastatic breast cancer in low- and middle-income countries: bridging the gap between clinical trials and real life.

Breast Cancer Res Treat 2020 Jun 29;181(3):693-694. Epub 2020 Apr 29.

Program of Mastology, Federal University of Goiás (UFG), 1ª Avenida, s/n, Setor Universitário, Goiânia, Goiás, CEP: 74.605-020, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05659-6DOI Listing

Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.

Breast Cancer Res Treat 2020 Jun 29;181(3):541-551. Epub 2020 Apr 29.

Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, NG7 2RD, UK.

Background: Breast cancer (BC) is a disease with variable morphology, clinical behaviour and response to therapy. Identifying factors associated with the progression of early-stage BC can help understand the risk of metastasis and guide treatment decisions. Myxovirus resistance 1 (MX1), which is involved in the cellular antiviral mechanism, plays a role in some solid tumours; however, its role in invasive BC remains unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05646-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220876PMC

Medical costs associated with metastatic breast cancer in younger, midlife, and older women.

Breast Cancer Res Treat 2020 Jun 28;181(3):653-665. Epub 2020 Apr 28.

Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Purpose: We estimated average medical costs due to metastatic breast cancer (mBC) among younger (aged 18-44), midlife (aged 45-64), and older women (aged 65 and older) by phase of care: initial, continuing, and terminal.

Methods: We used 2003-2014 North Carolina cancer registry data linked with administrative claims from public and private payers. We developed a claims-based algorithm to identify breast cancer patients who progressed to metastatic disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05654-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228827PMC